Tuberculosis and COVID-19, the new cursed duet: what differs between Brazil and Europe? / Tuberculose e COVID-19, o novo dueto maldito: quais as diferenças entre Brasil e Europa?
J. bras. pneumol
;
47(2): e20210044, 2021. tab, graf
Article
in English
| LILACS
| ID: biblio-1250196
ABSTRACT
ABSTRACT On April 1st, 2020, COVID-19 surpassed tuberculosis regarding the number of deaths per day worldwide. The combination of tuberculosis and COVID-19 has great potential for morbidity and mortality. In addition, the COVID-19 pandemic has had a significant impact on the diagnosis and treatment of tuberculosis. In this review article, we address concurrent tuberculosis and COVID-19, with particular regard to the differences between Brazil and Europe. In addition, we discuss priorities in clinical care, public health, and research.
RESUMO
RESUMO Em 1º de abril de 2020, a COVID-19 ultrapassou a tuberculose em número de óbitos por dia no mundo. A associação da tuberculose com a COVID-19 apresenta grande potencial de morbidade e mortalidade. Além disso, a pandemia de COVID-19 tem tido um impacto significativo no diagnóstico e tratamento da tuberculose. Neste artigo de revisão, abordamos tuberculose e COVID-19 concomitantes, com particular atenção às diferenças entre Brasil e Europa. Além disso, discutimos as prioridades em atendimento clínico, saúde pública e pesquisa.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
Tuberculosis
/
COVID-19
Limits:
Humans
Country/Region as subject:
South America
/
Brazil
/
Europa
Language:
English
Journal:
J. bras. pneumol
Journal subject:
Pulmonary Disease (Specialty)
Year:
2021
Type:
Article
Affiliation country:
Brazil
/
Italy
/
United kingdom
Institution/Affiliation country:
Fundação Oswaldo Cruz/BR
/
IRCCS/IT
/
Queen Mary University of London/GB
/
Universidade Federal do Rio Grande do Sul/BR
/
Universidade Federal do Rio de Janeiro/BR
Similar
MEDLINE
...
LILACS
LIS